Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $76.4 million.

  • Mereo BioPharma Group's Liabilities and Shareholders Equity fell 39.60% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.9 million, marking a year-over-year decrease of 15.09%. This contributed to the annual value of $76.4 million for FY2024, which is 14.87% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Liabilities and Shareholders Equity of $76.4 million as of FY2024, which was up 14.87% from $66.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Liabilities and Shareholders Equity registered a high of $170.4 million during FY2021, and its lowest value of $66.5 million during FY2023.
  • In the last 3 years, Mereo BioPharma Group's Liabilities and Shareholders Equity had a median value of $76.4 million in 2024 and averaged $73.4 million.
  • Per our database at Business Quant, Mereo BioPharma Group's Liabilities and Shareholders Equity skyrocketed by 110.82% in 2021 and then tumbled by 54.57% in 2022.
  • Mereo BioPharma Group's Liabilities and Shareholders Equity (Yearly) stood at $80.8 million in 2020, then spiked by 110.82% to $170.4 million in 2021, then crashed by 54.57% to $77.4 million in 2022, then dropped by 14.10% to $66.5 million in 2023, then climbed by 14.87% to $76.4 million in 2024.